Notably, our study is among the first to propose Naringin as a natural compound capable of simultaneously targeting CDK1 and WEE1, based on both docking affinity and dynamic binding stability—an aspect not explored in prior ovarian cancer studies. Here, CDK1 is linked to ovarian cancer.